Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?

Tytuł:
Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?
Autorzy:
Stieb S; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Mohamed ASR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Deshpande TS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Harp J; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Greiner B; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Garden AS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Cardoso R; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Phan J; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Reddy JP; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Morrison WH; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Rosenthal DI; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Frank SJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Fuller CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Brandon Gunn G; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Corporate Authors:
MD Anderson Head and Neck Cancer Symptom Working Group
Źródło:
Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2020 Mar 24; Vol. 22, pp. 98-105. Date of Electronic Publication: 2020 Mar 24 (Print Publication: 2020).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: [Shannon] : Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology, [2016]-
References:
Curr Treat Options Oncol. 2018 Nov 9;19(12):72. (PMID: 30411162)
Qual Life Res. 2016 Jun;25(6):1495-504. (PMID: 26589527)
Cancer Treat Rev. 2015 Feb;41(2):179-86. (PMID: 25499998)
J Neurosci. 2012 Mar 7;32(10):3474-84. (PMID: 22399770)
J Pharm Bioallied Sci. 2014 Jul;6(Suppl 1):S30-3. (PMID: 25210380)
Head Neck. 2014 Nov;36(11):1604-10. (PMID: 24115115)
Radiother Oncol. 2016 May;119(2):213-20. (PMID: 27165613)
Radiat Oncol. 2017 Sep 9;12(1):150. (PMID: 28888224)
Oral Oncol. 2013 Jun;49(6):634-42. (PMID: 23562564)
Ann Otol Rhinol Laryngol. 2017 Jul;126(7):548-554. (PMID: 28511547)
Support Care Cancer. 2015 Nov;23(11):3257-68. (PMID: 25851804)
Ann Oncol. 2017 May 1;28(5):969-984. (PMID: 28327968)
Radiother Oncol. 2012 Sep;104(3):343-8. (PMID: 22853852)
Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):459-67. (PMID: 10772298)
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14. (PMID: 27354125)
Dysphagia. 2014 Dec;29(6):663-70. (PMID: 25115856)
J Clin Oncol. 2012 May 20;30(15):1777-83. (PMID: 22508814)
Pract Radiat Oncol. 2015 Jul-Aug;5(4):e299-308. (PMID: 25544553)
Arch Otolaryngol Head Neck Surg. 1991 May;117(5):519-28. (PMID: 2021470)
BMC Cancer. 2011 Apr 12;11:128. (PMID: 21486431)
World J Otorhinolaryngol Head Neck Surg. 2018 Jun 28;4(1):11-28. (PMID: 30035257)
Ann R Coll Surg Engl. 2011 Nov;93(8):591-5. (PMID: 22041234)
Chem Senses. 2015 May;40(4):285-92. (PMID: 25800268)
Strahlenther Onkol. 2015 Jun;191(6):501-10. (PMID: 25747264)
JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):129-33. (PMID: 24337483)
Chem Senses. 2019 May 29;44(5):319-326. (PMID: 30957861)
Am J Clin Oncol. 2011 Oct;34(5):478-82. (PMID: 21537150)
J Clin Oncol. 1999 Mar;17(3):1008-19. (PMID: 10071296)
Cancer. 2014 Jul 1;120(13):1975-84. (PMID: 24711162)
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6. (PMID: 11448365)
Front Physiol. 2017 Mar 08;8:134. (PMID: 28337150)
Head Neck. 2007 Oct;29(10):923-31. (PMID: 17358040)
J Oral Maxillofac Surg. 2010 Sep;68(9):2164-8. (PMID: 20542366)
Head Neck. 2012 Jun;34(6):797-804. (PMID: 22127786)
Radiother Oncol. 2016 Feb;118(2):335-41. (PMID: 26777124)
Radiother Oncol. 2015 Oct;117(1):132-8. (PMID: 26403258)
Br J Radiol. 2011 Apr;84(1000):367-74. (PMID: 21415302)
Head Neck. 1993 Nov-Dec;15(6):485-96. (PMID: 8253555)
Arch Neurol. 2003 May;60(5):667-71. (PMID: 12756129)
Eur J Oncol Nurs. 2018 Dec;37:43-50. (PMID: 30473050)
Clin Oncol (R Coll Radiol). 2003 Jun;15(4):205-10. (PMID: 12846500)
Indian J Cancer. 2017 Apr-Jun;54(2):447-452. (PMID: 29469076)
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):981-91. (PMID: 17145528)
Grant Information:
P30 CA016672 United States CA NCI NIH HHS; R01 CA214825 United States CA NCI NIH HHS; R25 EB025787 United States EB NIBIB NIH HHS; R56 DE025248 United States DE NIDCR NIH HHS; R01 CA218148 United States CA NCI NIH HHS; P50 CA097007 United States CA NCI NIH HHS; R01 DE028290 United States DE NIDCR NIH HHS
Contributed Indexing:
Keywords: Oropharyngeal cancer; Quality of life; Radiotherapy; Recovery of function; Taste
Entry Date(s):
Date Created: 20200507 Latest Revision: 20220414
Update Code:
20240105
PubMed Central ID:
PMC7191583
DOI:
10.1016/j.ctro.2020.03.006
PMID:
32373720
Czasopismo naukowe
Background and Purpose: Taste impairment is a common radiation-induced toxicity in head and neck cancer (HNC) patients acutely. However, data on the potential for recovery and the time dependent course of late taste impairment are limited.
Materials and Methods: As part of an IRB-approved observational prospective study, HNC patients underwent serial surveys including the MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN). For our analysis, we extracted MDASI-HN taste item results from oropharyngeal cancer patients treated with intensity-modulated radiotherapy or volumetric modulated arc therapy and at least two taste assessments after ≥1 year from end of radiotherapy (RT).
Results: 1214 MDASI taste items from 326 patients between 1 and 13 years post-RT were included. Median prescribed dose to the high-dose clinical target volume (CTV1) was 66.0 Gy, with 180 patients (55%) receiving chemotherapy. Taste markedly improved in the first years from end of RT, but plateaued after year 5. In patients with taste assessment in subsequent years, a significant reduction in taste impairment was found from the second to the third year (p = 0.001) and tended towards significance from the third to the fourth year (p = 0.058). Multivariate analysis revealed treatment site as significant factor in the sixth year from RT and CTV1 dose and age in the seventh year.
Conclusion: Radiation-induced taste impairment may improve over an extended time interval, but becomes relatively stable from year 5 post-RT. Direct characterization of RT-induced taste impairment and the calculation of normal tissue complication probability should include consideration of the time-dependent course in taste recovery.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2020 The Authors.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies